Clinical and biological insights in HIV-associated cardiovascular disease in the era of highly active antiretroviral therapy

AIDS

Volumn 17, Issue SUPPL. 1, 2003, Pages

  Murphy, Robert L ^a,c   Barbaro, Giuseppe ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; ORAL ANTIDIABETIC AGENT; PROSTACYCLIN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TROGLITAZONE;

ATHEROGENESIS; BRAIN DISEASE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CONGESTIVE HEART FAILURE; COR PULMONALE; CORONARY ARTERY DISEASE; DIET; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE COURSE; DISEASE EXACERBATION; DISEASE PREDISPOSITION; EXERCISE; FOLLOW UP; HAZARD ASSESSMENT; HEART DILATATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPETENCE; INCIDENCE; INFLAMMATION; INSULIN RESISTANCE; LACTIC ACIDOSIS; LIFESTYLE; LIPODYSTROPHY; MORTALITY; MYOCARDITIS; PATHOGENESIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; RETROSPECTIVE STUDY; RISK FACTOR; SEPSIS; SHORT SURVEY; SIDE EFFECT; SMOKING; SURVIVAL RATE; SURVIVAL TIME; VIRUS INFECTION;

EID: 0037529281     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200304001-00001     Document Type: Short Survey

References (24)

1. Lipshultz SE, Easley KA, Orav EJ, et al. Cardiac dysfunction and mortality in HIV-infected children. The Prospective P2C2 HIV Multicenter Study. Circulation 2000, 102:1542-1548.
2. Barbaro G, Fisher SD, Lipshultz SE. Pathogenesis of HIV-associated cardiovascular complications. Lancet Infect Dis 2001, 1:115-124.
3. Lewis W. Cardiomyopathy in AIDS: a pathophysiological perspective. Prog Cardiovasc Dis 2000, 43:151-170.
4. Barbaro G. Cardiovascular manifestations of HIV infection. J R Soc Med 2001, 94:384-390.
5. Barbaro G, Di Lorenzo G, Soldini M, et al. The intensity of myocardial expression of inducible nitric oxide synthase influences the clinical course of human immunodeficiency virus-associated cardiomyopathy. Circulation 1999, 100:633-639.
6. Lipshultz SE. Dilated cardiomyopathy in HIV-infected patients [editorial]. N Engl J Med 1998, 339:1153-1155.
7. Barbaro G. Cardiovascular manifestations of HIV infection. Circulation 2002, 106:1420-1425.
8. Barbaro G, Di Lorenzo G, Soldini M, et al. Clinical course of cardiomyopathy in HIV-infected patients with or without encephalopathy related to the myocardial expression of TNF-α and iNOS. AIDS 2000, 14:827-838.
9. Pugliese A, Isnardi D, Saini A, Scarabelli T, Raddino R, Torre D. Impact of higly active antiretroviral therapy in HIV-positive patients with cardiac involvement. J Infect 2000, 40:282-284.
10. Pellicelli A, Barbaro G, Palmieri F, et al. Primary pulmonary hypertension in HIV disease: a systematic review. Angiology 2001, 52:31-41.
11. Barbaro G, Barbarini G, Pellicelli AM. HIV-associated coronary arteritis in a patient with fatal myocardial infarction. N Engl J Med 2001, 344:1799-1800.
12. Miller J, Carr A, Smith D, et al. Lipodystrophy following antiretroviral therapy of primary HIV infection. AIDS 2000, 14:2406-2407.
13. Mooser V, Carr A. Antiretroviral therapy-associated hyperlipidemia in HIV disease. Curr Opin Lipidol 2001, 12:313-319.
14. Henry K, Melrow H, Huebsch J, et al. Severe coronary heart disease with protease inhibitors [letter]. Lancet 1998, 351:1328.
15. Behrens G, Schmidt H, Meyer D, Stoll M, Schmidt RE. Vascular complications associated with use of HIV protease inhibitors [letter]. Lancet 1998, 351:1958.
16. Jutte A, Schwenk A, Franzen C, et al. Increasing morbidity from myocardial infarction during HIV protease inhibitor treatment? [Letter]. AIDS 1999, 13:1796-1797.
17. Flynn TE, Bricker LA. Myocardial infarction in HIV-infected men receiving protease inhibitors [letter]. Ann Intern Med 1999, 131:548.
18. Passalaris JD, Sepkowitz KA, Glesby MJ. Coronary artery disease and human immunodeficiency virus infection. Clin Infect Dis 2000, 31:787-797.
19. Rickerts V, Brodt H, Staszewski S, Stille W. Incidence of myocardial infarctions in HIV-infected patients between 1983 and 1998: the Frankfurt HIV-cohort study. Eur J Med Res 2000, 5:329-333.
20. Witz M, Lehmann J, Korzets Z. Acute brachial artery thrombosis as the initial manifestation of human immunodeficiency virus infection. Am J Hematol 2000, 64:137-139.
21. Hadigan C, Meigs JB, Rabe J, et al. Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance. J Clin Endocrinol Metab 2001, 86:939-943.
22. Nair R, Robbs JV, Chetty R, Naidoo NG, Woolgar J. Occlusive arterial disease in HIV-infected patients: a preliminary report. Eur J Vasc Endovasc Surg 2000, 20:353-357.
23. Dube MP, Sprecher D, Henry WK, et al. Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group. Clin Infect Dis 2000, 31:1216-1224.
24. Currier JS. How to manage metabolic complications of HIV therapy: what to do while we wait for answers. AIDS Read 2000, 10:162-169.